Business Wire

Airbus Defence and Space Partners with AI Start-Up NeuralAgent on the Future Combat Air System (FCAS) Project

Share

Airbus Defence and Space, a leader in the aerospace industry, and NeuralAgent, an innovative AI start-up, have signed two contracts that will help shape the Future Combat Air System (FCAS) programme. This tri-national programme led by the Ministries of Defence from France, Germany and Spain marks a significant step forward in strengthening European Defence Systems, notably through cutting-edge artificial intelligence. This partnership between Airbus and NeuralAgent will contribute to the FCAS’ Combat Cloud, as part of the global phase 1B contract.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530772952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 1: Signing Ceremony, People from left to right, Jennifer Klaschka- Marketing and Operations at NeuralAgent, Dr. -Ing Onur Deniz CEO at NeuralAgent, Dirk Sprünken Procurement at Airbus, Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus, Luis Mager – Procurement at Airbus (Photo: Business Wire)

The partnership focuses on bridging the innovation gap with an AI-defined, non-jammable, resilient, and self-organizing network and system architectures in the air, on the ground or in space. The aim is to automate and optimize the response times of an unlimited number of combat nodes, reducing them to real time or milliseconds. This initiative will leverage Airbus Defence and Space's advanced infrastructure and NeuralAgent’s cutting-edge decentralized AI technology to deliver redundant, explainable, and high-performant collaborative Agents under dynamic environments. This aims to outperform costly central AI-Approaches with a single point of failure against jamming. Together, they seek to transform defense capabilities with unprecedented and distributed autonomous intelligence of large number of combat nodes.

Dr. -Ing Onur Deniz, CEO of NeuralAgent, emphasized the importance of this collaboration: "This contract is a pivotal achievement for NeuralAgent as it allows us to not only redefine the future of AI-defined Secure and Resilient Networks through our foundational AI-Agent Models but also extends our reach into dual-use cases for commercial industries from space to ground, supporting scalable innovation across the EU."

Juan Emilio Murillo Martinez, Head of Procurement Software and Cyber Security at Airbus Defence and Space, highlighted the benefits of this partnership: "Working with disruptive AI start-ups such as NeuralAgent, will propel our innovation efforts and help us stay ahead with the latest AI trends. This collaboration will enhance our capabilities in both legacy and future systems, ensuring we remain at the forefront of technological advancements."

This strategic partnership between Airbus Defence and Space and NeuralAgent aims to transform European defense AI capabilities, showcasing their commitment to innovation and leadership in the EU's biggest defense project.

About Airbus Defence and Space

Airbus Defence and Space is a division of Airbus Group responsible for defence and aerospace products and services. The company is a leader in designing, developing, and manufacturing military aircraft, space systems, and connected intelligence systems and services.

About NeuralAgent

NeuralAgent is an AI start-up specializing in the development of Decentralized AI-Agent Foundation Models for distributed autonomous intelligence and shaping the future of Telecoms, Mobility, NewSpace, Robotics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, contact: info@neuralagent.ai

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release

Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye